The earnings call highlighted significant progress in clinical trials and regulatory pathways, particularly in Japan, with promising partnership discussions. However, increased R&D expenses, a rise in net loss, and low cash reserves present challenges. The sentiment is cautiously optimistic with a focus on regulatory approvals and strategic partnerships.

Company Guidance -

Q3 2025

In the recent BioCardia conference call, several key metrics and developments were discussed regarding their ongoing and future activities. The CardiAMP Heart Failure trial showed promising results, with the treatment group experiencing a lower incidence of all-cause death and nonfatal major adverse cardiac events (MACE) compared to the control group over 24 months, with a p-value of 0.17. A statistically significant improvement in a composite endpoint was observed in a subgroup with elevated NT-proBNP, with a p-value of 0.02. BioCardia is pursuing regulatory approval in Japan and the United States, with a crucial meeting with Japan's PMDA scheduled for mid-Q4 2025, potentially paving the way for market entry. The company is also focusing on their Helix biotherapeutic delivery system, seeking FDA approval via the de novo 510(k) pathway. Financially, BioCardia reported an increase in R&D expenses to $1.4 million for Q2 2025, up from $0.8 million in Q2 2024, while SG&A expenses decreased to $0.7 million from $0.9 million over the same period. The company's cash and cash equivalents totaled $980,000 at quarter's end, with additional funds raised through stock sales. BioCardia aims to maintain efficient resource use and is exploring potential partnerships to enhance shareholder value.

CardiAMP Heart Failure Trial Success

The CardiAMP Heart Failure treatment group showed lower incidence of all-cause death and nonfatal MACE compared to the control group over a 24-month period. Additionally, the composite endpoint of all-cause death, nonfatal MACE, and quality of life was statistically significant in patients with elevated NT-proBNP, with a p-value of 0.02.

Regulatory Progress in Japan

BioCardia has submitted the clinical package of the CardiAMP Heart Failure trial to Japan's PMDA and anticipates an in-person meeting in Q4 2025, potentially leading to market entry approval in Japan.

Data Safety Monitoring Board Review Success

A successful data safety monitoring board review was conducted for the CardiALLO allogeneic mesenchymal stem cell therapy in ischemic heart failure (BCDA-03) program.

Partnership Opportunities

Active discussions are ongoing for partnerships involving the Helix biotherapeutic delivery platform and the Morph DNA technology, with interest from firms in the cardiac electrophysiology market.

BioCardia (BCDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.21 / -	-0.61	―	―	―
Aug 11, 2025	2025 (Q2)	-0.50 / -0.40	-0.88	54.55% (+0.48)	―
May 14, 2025	2025 (Q1)	- / -0.59	-1.35	56.30% (+0.76)	―
Mar 26, 2025	2024 (Q4)	-0.63 / -0.06	-1.35	95.56% (+1.29)	―	―
Nov 13, 2024	2024 (Q3)	-1.19 / -0.61	-1.8	66.11% (+1.19)	―
Aug 13, 2024	2024 (Q2)	-0.10 / -0.88	-2.55	65.49% (+1.67)	―
May 14, 2024	2024 (Q1)	- / -1.35	-2.55	47.06% (+1.20)	―
Mar 27, 2024	2023 (Q4)	-1.13 / -1.35	-2.55	47.06% (+1.20)	―
Nov 08, 2023	2023 (Q3)	-1.80 / -1.80	-2.55	29.41% (+0.75)	―
Aug 09, 2023	2023 (Q2)	-2.35 / -2.55	-2.1	-21.43% (-0.45)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$1.79	$1.68	-6.15%
May 14, 2025	$2.77	$2.32	-16.25%
Mar 26, 2025	$2.55	$2.68	+5.10%
Nov 13, 2024	$2.35	$2.02	-14.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioCardia Inc (BCDA) report earnings?

BioCardia Inc (BCDA) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is BioCardia Inc (BCDA) earnings time?

BioCardia Inc (BCDA) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BCDA EPS forecast?

BCDA EPS forecast for the fiscal quarter 2025 (Q3) is -0.21.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing